Skip to main content
Premium Trial:

Request an Annual Quote

NIH Earmarks $300,000 to Support Biological Assay Development in Sickle Cell Disease

NEW YORK, Jan. 3 (GenomeWeb News) - The National Institutes of Health will award $300,000 during 2005 to advance the development of biological assays related to sickle cell disease.


According to the NIH, the money is expected to be used to fund three new grants under a request for applications for projects the focus on the "development of scientifically and technologically robust screening assays that can be automated and used for the identification of compounds that can be utilized in both basic research and therapeutics development programs in sickle cell disease."


The proposed assay protocols "must employ reagents and readouts that can be used in the high-throughput molecular screen environments," the NIH said. "Funding will be provided to enable investigators to develop and transform promising assay protocols for sickle cell disease by demonstrating the responsiveness and robustness required for use in HTS."


Letters of intent from RFA responders are due March 25, and applications are due April 26. Additional details about the RFA can be found  here.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.